Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415

1.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Rickenbach M, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Apr 15;46(8):1299-309. doi: 10.1086/528863.

2.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
3.

Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group.

Antivir Ther. 2004 Jun;9(3):315-23.

PMID:
15259894
4.

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.

Trotta MP, Bonfigli S, Ceccherini-Silberstein F, Bellagamba R, D'Arrigo R, Soldani F, Zaccarelli M, Concetta Bellocchi M, Lorenzini P, Marconi P, Boumis E, Forbici F, Comandini UV, Tozzi V, Narciso P, Federico Perno C, Antinori A.

J Med Virol. 2006 May;78(5):535-41.

PMID:
16555278
5.

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.

Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):15-21.

PMID:
12792350
6.

K65R, TAMs and tenofovir.

Miller MD.

AIDS Rev. 2004 Jan-Mar;6(1):22-33. Review.

PMID:
15168738
7.

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.

Wirden M, Marcelin AG, Simon A, Kirstetter M, Tubiana R, Valantin MA, Paris L, Bonmarchand M, Conan F, Kalkias L, Katlama C, Calvez V.

J Med Virol. 2005 Jul;76(3):297-301.

PMID:
15902696
8.

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.

McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1340-50.

PMID:
15483463
9.

Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.

Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.

Antivir Ther. 2006;11(6):827-30.

PMID:
17310827
10.

The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

Theys K, Vercauteren J, Abecasis AB, Libin P, Deforche K, Vandamme AM, Camacho R.

Infect Genet Evol. 2009 Jul;9(4):683-8. doi: 10.1016/j.meegid.2008.10.013. Epub 2008 Nov 6.

PMID:
19038365
11.

HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.

Boucher S, Recordon-Pinson P, Ragnaud JM, Dupon M, Fleury H, Masquelier B.

HIV Med. 2006 Jul;7(5):294-8.

12.

Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R; COL40263 study.

J Antimicrob Chemother. 2010 Feb;65(2):307-15. doi: 10.1093/jac/dkp419. Epub 2009 Dec 15.

13.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

Rey D, Krebs M, Partisani M, Hess G, Cheneau C, Priester M, Bernard-Henry C, de Mautort E, Lang JM.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):530-4.

PMID:
17057610
14.

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD.

AIDS. 2002 Jun 14;16(9):1227-35.

PMID:
12045487
15.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

Pérez-Elías MJ, Moreno S, Gutiérrez C, López D, Abraira V, Moreno A, Dronda F, Casado JL, Antela A, Rodríguez MA.

AIDS. 2005 Apr 29;19(7):695-8.

PMID:
15821395
16.

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M.

J Infect Dis. 2004 Mar 1;189(5):837-46. Epub 2004 Feb 10.

17.

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.

Antivir Ther. 2006;11(2):213-21.

PMID:
16640102
18.

Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.

Antoniou T, Park-Wyllie LY, Tseng AL.

Pharmacotherapy. 2003 Jan;23(1):29-43. Review.

PMID:
12523458
19.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

20.

Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort.

Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7.

PMID:
19669091
Items per page

Supplemental Content

Write to the Help Desk